#1726
A Long-Term Complete Response (CR) of Avelumab in Patient (pt) with Advanced Merkel Cell Carcinoma (MCC)
Introduction:
MCC is a rare and aggressive cutaneous neuroendocrine cancer linked to exposure to the Merkel Polyomavirus (MCPyV). Cisplatin and VP16 chemo may be an effective treatment for metastatic MCC, but responses are often transient. The blockade of programmed death 1 (PD-1) immune inhibitory pathway by avelumab, an anti-PD-L1 checkpoint inhibitor, is being investigated in solid neoplasms. This strategy can also be of interest in MCC because these tumors often express PD-L1
Conference:
14th Annual ENETSConcerence (2017)
Presenting Author:
Pusceddu S
Authors:
Femia D,
Prinzi N,
Vernieri C,
Lo Russo G,
Concas L,
Keywords:
Merkel cell carcinoma,
Avelumab,
#1725
Safety of Lanreotide 120 mg ATG (LAN) in Combination with Metformin (MET) in Patients (pts) with Progressive Advanced Well-Differentiated (WD) Gastro-Intestinal (GI) or Lung Carcinoids. A Pilot, One-Arm, Open-Label, Prospective Study: The MetNET-2 Trial
Introduction:
Anti proliferative effect of LAN ATG 120 mg has been investigated in 204 GI-NET pts in Clarinet study with a 53% reduction in risk of death/progression vs placebo. An increasing number of trials have associated MET with better outcome in cancer pts due to a reduction of insulin/IGF1 levels and modulation of AMPK and TSC1-2/mTOR. The retrospective PRIME-net study conducted on 445 Italian pts, suggest that addition of MET to everolimus and/or SSA provides clinical benefit in diabetic pancreatic NETs.
Conference:
14th Annual ENETSConcerence (2017)
Presenting Author:
pusceddu s
Authors:
Prinzi N,
Femia D,
Concas L,
Lo Russo G,
Vernieri C,
Keywords:
lanreotide,
metformin,
